Company Overview and News

0
'He asks us to front up $1bn': Indian billionaire under fire over Adani rail line

2018-07-19 theage.com.au
Adani's rail line to service its controversial Queensland mine should be in public hands and the Indian billionaire Gautam Adani should be paying for it, says former state under treasurer Sir Leo Hielscher.
XQL

0
'He asks us to front up $1bn': Indian billionaire under fire over Adani rail line

2018-07-19 smh.com.au
Adani's rail line to service its controversial Queensland mine should be in public hands and the Indian billionaire Gautam Adani should be paying for it, says former state under treasurer Sir Leo Hielscher.
XQL

0
'Bleeding cash': Ipswich Council's secretive development arm loses $80m

2018-06-27 abc.net.au
A strife-torn Queensland council has lost ratepayers more than $80 million through a secretive property development arm that could prove a costly timebomb, expert analysis obtained by the ABC reveals.
XQL

0
Big firms call for new SEQ city deal to deliver infrastructure boost

2018-06-06 smh.com.au
Queensland’s major construction and engineering companies have called on the state government to back a new city deal for south-east Queensland, as it did for Townsville in 2016, ahead of next Tuesday's budget.
XQL

0
Hospital parking stress in Brisbane's north to ease

2018-04-27 smh.com.au
Hospital parking stress in Brisbane’s north is set to ease with the state government to borrow money for a multi-storey car park.
XQL

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...